SUMMARY  

• Per Recommendation 19 of the 2022 Veteran Affairs/Department of Defense (VA/DoD) Clinical Practice Guidelines for the Management of Major Depressive Disorder (MDD), SPRAVATO is suggested as an augmentation option in patients with MDD who have not responded adequately to several pharmacologic trials.¹
• Per Recommendation 12, the guidelines suggest against SPRAVATO being used as initial pharmacotherapy for the treatment of uncomplicated MDD.¹
• The guidelines also provide general recommendations for the duration of MDD treatment. Patients should continue to take antidepressant medication even after feeling better. To decrease the risk of relapse in patients who achieve remission after a first episode of MDD, patients are recommended to continue antidepressant treatment for at least 6 months. Patients who have had at least 2 episodes of MDD or are at a high risk of relapse or recurrence are recommended to continue pharmacotherapy for at least 12 months and possibly indefinitely.¹